Based on the prediction of network pharmacology, PI3K p85, AKT1, GSK3β, and Myc proteins in the PI3K-AKT signal pathway were selected and used to verify the mechanism of action of EJP in treating T2DM at the mRNA level by RT-PCR. This evidence concerns the gene AKT1 and type 2 diabetes mellitus.